Guillain-Barré Syndrome

Detailed Overview

GBS is a neurologic emergency because up to 30% of patients will develop respiratory muscle failure requiring mechanical ventilation, and autonomic dysfunction can cause lethal arrhythmias. The most common subtype in North America and Europe is Acute Inflammatory Demyelinating Polyneuropathy (AIDP). Axonal variants (AMAN, AMSAN) are more common in Asia and generally portend a slower recovery. Rapid diagnosis based on clinical presentation, supported by lumbar puncture and electromyography, is critical to initiate immunomodulatory therapy (IVIG or plasmapheresis) and alter the natural course of the disease.

Epidemiology & Demographics

Annual incidence is 1-2 per 100,000 globally. Affects all age groups, but incidence increases by 20% with every 10-year increase in age. Males are affected slightly more often than females (1.5:1).

Etiological Mechanism

Considered an autoimmune disease triggered by molecular mimicry. About two-thirds of cases are preceded by an infectious illness 1-6 weeks prior to the onset of neurologic symptoms. Campylobacter jejuni is the most common identified infectious trigger (associated with severe axonal variants and anti-GM1 antibodies). Other triggers include Cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, and Zika virus.

Primary Causes

Post-infectious molecular mimicry (Campylobacter jejuni, CMV, Zika). Extremely rare instances associated with vaccinations (e.g., 1976 Swine Flu vaccine), though the background risk of GBS is much higher from influenza infection itself.

• Recent Gastrointestinal Infection: Particularly Campylobacter jejuni infection, heavily linked to the AMAN subtype.
• Recent Respiratory Infection: Viral URIs frequently precede AIDP.

Pathogenesis is driven by molecular mimicry. Lipooligosaccharides on the surface of infectious agents (like C. jejuni) structurally resemble gangliosides (e.g., GM1, GD1a) found on peripheral nerve myelin or the axonal axolemma. The immune system generates antibodies against the pathogen, which cross-react with the peripheral nerve gangliosides. This binding activates the complement cascade (MAC complex formation) and recruits macrophages. In AIDP, macrophages strip the myelin sheath, causing conduction block and flaccid weakness. In axonal forms (AMAN), the attack is directly against the axon nodes of Ranvier, leading to severe axonal degeneration.

Characteristic Clinical Presentation

• Ascending Weakness: Symmetric, progressive weakness starting in the distal lower extremities (feet/legs) and moving proximally to the arms and facial muscles over hours to days.
• Paresthesias: Tingling or 'pins and needles' sensation in the toes and fingertips, often the earliest symptom.
• Severe Radicular Back Pain: Deep, aching pain in the lower back or thighs due to nerve root inflammation.

Physical Examination Signs

• Areflexia or diffuse hyporeflexia (absent deep tendon reflexes).
• Bilateral facial nerve palsy (CN VII) occurs in up to 50% of cases.
• Autonomic dysfunction: Tachycardia, wide fluctuations in blood pressure, or urinary retention.

• Respiratory Failure: Paralysis of the diaphragm and intercostal muscles requiring intubation and mechanical ventilation.
• Dysautonomia-related Cardiac Arrest: Vagal instability can lead to profound bradycardia or asystole.

Diagnostic Criteria & Guidelines

Clinical diagnosis based on progressive symmetric weakness and areflexia. Supported by cerebrospinal fluid (CSF) analysis showing albuminocytologic dissociation and Nerve Conduction Studies (NCS) showing demyelination or axonal loss.

Differential Diagnosis

• Myasthenia Gravis (typically fluctuating, starts with ocular/bulbar muscles)
• Tick Paralysis
• Botulism (descending paralysis)

Laboratory Tests & Biomarkers

• Cerebrospinal Fluid (CSF) Analysis: Albuminocytologic dissociation: Elevated CSF protein (> 45 mg/dL) with normal WBC count (< 50 cells/μL). Note: may be normal in the first week.
• Serum Ganglioside Antibodies: Anti-GQ1b strongly positive in Miller Fisher variant; Anti-GM1 positive in AMAN.

Imaging Modalities & Findings

• Spinal MRI with contrast:

• Progressive Phase
  Symptoms worsen daily, peaking by 2-4 weeks.
• Plateau Phase
  Symptoms stabilize for weeks to months without further progression.
• Recovery Phase
  Gradual remyelination and axonal regeneration; strength returns slowly over months to years.

Second-Line & Adjunctive Therapy

Supportive care in ICU setting is the cornerstone. Aggressive physical and occupational therapy once the patient is stable.

Surgical & Procedural Management

Tracheostomy may be required for patients with prolonged respiratory failure to facilitate weaning from the ventilator. Percutaneous Endoscopic Gastrostomy (PEG) for severe bulbar dysfunction.

Recommended Lifestyle Changes

• Extensive, long-term neuro-rehabilitation focusing on gait training and motor recovery.
• Preventive measures for prolonged immobility (DVT prophylaxis, pressure ulcer care).

Patient Counseling & Advice

Recovery is a marathon, not a sprint. 80% of patients recover walking independently, but it can take 6-12 months, and mild residual deficits (like foot drop or fatigue) are common. The risk of recurrence is very low (about 2-5%).

Follow-Up & Monitoring Schedule

During acute phase: Monitor Forced Vital Capacity (FVC) and Negative Inspiratory Force (NIF) every 4 hours. Intubate if FVC < 20 mL/kg or NIF drops below -30 cm H2O. Continuous telemetry monitoring for arrhythmias.

Preventive Strategies

No specific prevention. Practice safe food handling (C. jejuni is often foodborne via undercooked poultry) and general hand hygiene.

Mortality is 3-7% (mostly from autonomic dysfunction, pneumonia, or pulmonary embolism). Around 20% remain with significant disability at 1 year. Most have full or near-full functional recovery.